As shown in Figures S12A–S12R, in 14 of 18 malignancies, elevated LIGHT expression conferred a survival advantage, with superior 3- or 5-year survival in the high-expression cohorts compared to low-expression groups, particularly in breast invasive carcinoma, rectum adenocarcinoma, liver hepatocellular carcinoma, skin cutaneous melanoma, and ovary serous cystadenocarcinoma. This evidence concerns the gene TNFSF14 and invasive breast carcinoma.